An initial double-blind cross-over study and a subsequent double-blind comparative study against placebo tablets has shown Bradilan (tetranicotinoylfructose) to be an effective treatment of chilblains. The difference between the active and placebo group was highly significant statistically with p < ·001
Get full access to this article
View all access options for this article.
References
1.
AndrewsGJudgeTGWalkeyF (1973) The Action of Tetranicotinoylfructose in Peripheral Vascular Disease. Practitioner211, 83
2.
AntcliffACBouhoutsosJMartinPCGMorrisWT (1973) The Effect of Tetranicotinoylfructose (Bradilan) on the Digital Blood Flow of Patients with Primary and Secondary Raynaud's Phenomenon. Meeting of International College of Angiology, Lisbon, July 1973
3.
GourlayRJ (1948) The Problem of Chilblains with a Note on their Treatment with Nicotinic Acid. British Medical Journal1, 336
4.
HoltiGNewellDJPooleHG (1971) Tetranicotinoylfructose in Disorders of Digital Blood Flow. Practitioner207, 654
